Clinical trial
A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Temporal Lobe Epilepsy (MTLE)
NCT06422923 is registered in ClinicalTrials.gov with Neurona Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Temporal Lobe Epilepsy (MTLE)
- Lead sponsor
- Neurona Therapeutics
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- November 14, 2024
- Completion date
- June 15, 2042
- Enrollment
- 10 (estimated)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.